178 related articles for article (PubMed ID: 11060734)
1. Evaluation of mitoxantrone for the treatment of multiple sclerosis.
Jain KK
Expert Opin Investig Drugs; 2000 May; 9(5):1139-49. PubMed ID: 11060734
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
3. [Mitoxantrone].
Pericot I; Montalban X
Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone therapy in rapidly worsening multiple sclerosis.
Benesova Y; Stourac P; Beranek M; Kadanka Z
Bratisl Lek Listy; 2005; 106(3):141-3. PubMed ID: 16026151
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis.
Gonsette RE
Expert Opin Pharmacother; 2004 Apr; 5(4):747-65. PubMed ID: 15102561
[TBL] [Abstract][Full Text] [Related]
6. Mitoxantrone in progressive multiple sclerosis: when and how to treat?
Gonsette RE
J Neurol Sci; 2003 Feb; 206(2):203-8. PubMed ID: 12559512
[TBL] [Abstract][Full Text] [Related]
7. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
[TBL] [Abstract][Full Text] [Related]
8. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
Ramtahal J; Jacob A; Das K; Boggild M
J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
Foo EC; Russell M; Lily O; Ford HL
Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
[TBL] [Abstract][Full Text] [Related]
10. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
11. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
12. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Rivera VM; Jeffery DR; Weinstock-Guttman B; Bock D; Dangond F
BMC Neurol; 2013 Jul; 13():80. PubMed ID: 23841877
[TBL] [Abstract][Full Text] [Related]
13. Review of mitoxantrone in the treatment of multiple sclerosis.
Jeffery DR; Herndon R
Neurology; 2004 Dec; 63(12 Suppl 6):S19-24. PubMed ID: 15623665
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
Hamzehloo A; Etemadifar M
Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351
[TBL] [Abstract][Full Text] [Related]
15. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
16. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
Stüve O; Kita M; Pelletier D; Fox RJ; Stone J; Goodkin DE; Zamvil SS
Mult Scler; 2004 Jun; 10 Suppl 1():S58-61. PubMed ID: 15218811
[TBL] [Abstract][Full Text] [Related]
18. [Mitoxantrone for the treatment of patients with multiple sclerosis].
Komori M; Kondo T; Tanaka M
Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients.
Montú MB; Arruda WO; de Oliveira Mde S; Ramina R
Arq Neuropsiquiatr; 2005 Jun; 63(2A):225-7. PubMed ID: 16100967
[TBL] [Abstract][Full Text] [Related]
20. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
